Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has approved an expanded indication for Eli Lilly and Company’s Jaypirca (pirtobrutinib) as a first-line treatment for adults with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who do not have a 17p deletion.
Both CLL and SLL are slow-growing non-Hodgkin lymphomas that originate in lymphocytes. Credit: Saiful52/Shutterstock.com.
Subscribe to our email newsletter
Jaypirca is a non-covalent Bruton tyrosine kinase (BTK) inhibitor and is administered orally as 50mg or 100mg tablets to achieve a daily 200mg dose.
The regulatory decision is supported by data from the primary analysis of the global, open-label Phase III BRUIN CLL-313 clinical study.
The trial randomised 282 treatment-naive patients to receive either single-agent pirtobrutinib or a chemoimmunotherapy regimen of bendamustine and rituximab.
Over a median follow-up period of 28 months, pirtobrutinib demonstrated a statistically significant improvement in progression-free survival assessed by an independent review committee, recording a hazard ratio of 0.20.
Median progression-free survival was not reached in the pirtobrutinib cohort compared to 33.5 months in the comparator arm. The overall response rate reached 94% for pirtobrutinib and 81% for the control group.
Lilly Oncology executive vice-president and president Jacob Van Naarden said: “This additional approval for Jaypirca, based on BRUIN CLL-313, marks a significant step forward, expanding its potential to reach more patients who may benefit – this time as an initial treatment for certain previously untreated patients with CLL or SLL.
“This milestone underscores Jaypirca’s versatility in the CLL continuum of care, from the first-line setting for appropriate patients to its valuable role in the relapsed or refractory post-covalent BTK inhibitor setting, reinforcing Jaypirca’s broad applicability as a meaningful treatment option for people with CLL or SLL.”
During the Phase III trial, serious adverse reactions occurred in 28% of patients treated with Jaypirca, with pneumonia observed in 5%. Adverse events resulted in dose reductions for 3.6% of patients and treatment discontinuation for 4.3%.
The National Comprehensive Cancer Network guidelines include Jaypirca as a Category 2A recommendation for untreated CLL/SLL patients without 17p deletions who are older with cardiac comorbidities.
It is also listed as a Category 1 preferred option for patients with relapsed or refractory disease following prior covalent BTK inhibitor therapy.
Both CLL and SLL are slow-growing non-Hodgkin lymphomas that originate in lymphocytes.
Last month, the US FDA approved Lilly’s Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin injection for adults with type 2 diabetes (T2D).
